more featured news

Featured
Nordic Healthcare Conference, November 25, 2025, Oslo

Hosted by the DNB//Back Bay Healthcare Partnership, the NAHC unites large and mid-cap public and private IPO-ready US and Nordic life science companies. Participating companies showcase leading products that offer substantial advancements in patient care, making them highly appealing investment opportunities. 

The 10th Annual Nordic-American Healthcare Conference: MARCH 25-26, 2026 New York City

Hosted by the DNB//Back Bay Healthcare Partnership, the NAHC unites large and mid-cap public and private IPO-ready US and Nordic life science companies. Participating companies showcase leading products that offer substantial advancements in patient care, making them highly appealing investment opportunities. 

Reality check: Unpacking the $150BGLP-1 market forecasts

Market expectations for GLP-1 agonists have been high for some time. But in the past year, sales forecasts have gone stratospheric.

BIO International

DNB//Back Bay is pleased to sponsor the BIO International Convention, the largest and most comprehensive event for biotechnology, representing the full ecosystem of biotech with 20,000 industry leaders from across the globe.

As Money Pours Into Weight Loss Drugs, Physicians Prioritize Efficacy, Access

With biopharma pouring more money than ever into weight loss medicines, physicians would like to see improved GLP-1 drugs. But the goals of the two parties are not in full alignment, according to a new study from financing partner DNB Markets and strategic advisory firm Back Bay Life Science Advisors.

Obesity Drug Development: Still Room to Grow
 

featured transactions

View All Transactions

Diversity Within Our Walls and Across Our Community

Back Bay is built on an appreciation of unique perspectives, a passion for creative approaches, and the ability to listen.

LEARN MORE